Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru
旨在减少间日疟原虫传播的集中集中药物管理(fMDA),这是秘鲁的一项实用整群随机对照试验
基本信息
- 批准号:10680477
- 负责人:
- 金额:$ 126.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-10 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdherenceAftercareAminoquinolinesAntimalarialsApplied ResearchBloodCase ManagementChloroquineClinicalCommunicable DiseasesCommunitiesConsentCost MeasuresCountryDataDetectionDiagnosticDoseDrug TargetingDrug resistanceEffectivenessEligibility DeterminationFamilyGenetic VariationGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyHalf-LifeHealth systemHemolysisHouseholdIncidenceIndividualInfectionInterventionLifeLiverMalariaMass ScreeningMeasuresMicroscopyMissionNational Institute of Allergy and Infectious DiseaseOutcomePeruPharmaceutical PreparationsPlasmodium falciparumPlasmodium vivaxPoliciesPopulationPrevalencePrimaquinePublic HealthRandomizedRandomized, Controlled TrialsRecommendationRelapseSafetySeasonsSerious Adverse EventSeroprevalencesTestingVivax Malariaadverse event riskarmasexualburden of illnesscomparative efficacycomparison controlcostcost effectivecost effectivenesscost-effectiveness ratiodensityeffectiveness evaluationfollow-uphigh riskimprovedincremental cost-effectivenessindexinginfection riskmembermeternovel therapeuticsopen labelpharmacovigilancepoint of care testingpreventprimary outcomeprophylacticpublic health relevancerapid testrisk minimizationsecondary endpointsecondary outcomestandard of caretooltransmission blockingtransmission processtreatment armtreatment effecturban areavector control
项目摘要
Project Summary/Abstract
In most countries approaching elimination, Plasmodium vivax (Pv) represents an increasing proportion relative
to P. falciparum (Pf). Mass drug administration (MDA), as a way target subpatent, asymptomatic infections, is
recommended for P. falciparum elimination, but the recommendation does not extend to P. vivax given limited
evidence, tools, and safety concerns. The objective of our study is to evaluate the long-term impact, safety,
and cost-effectiveness of focal MDA (fMDA) for Pv transmission reduction. To test our hypothesis that fMDA, in
addition to standard aggressive interventions, will safely reduce transmission, we propose a 3-year open-label
CRCT in the low endemic setting of Loreto Region, Peru. Villages or clusters will be randomized to control or
fMDA. The control arm will receive standard interventions (vector control, symptomatic case management, and
active case detection of asymptomatic cases). The treatment arm will receive standard interventions plus fMDA,
which will utilize a new drug for radical cure of P. vivax, tafenoquine, and a new quantitative glucose 6
phosphate dehydrogenase (G6PD) deficiency rapid test to support safe administration of tafenoquine. fMDA
will be targeted to consenting and eligible high-risk villagers, defined as household members and neighbors of
recent Pv index cases. fMDA will be conducted in 2 rounds per year, two months apart during the low malaria
season, and over 3 years. Eligibility will be re-assessed each year, and prior to each fMDA round. Specific
aims are to: 1) Determine the effectiveness of fMDA to reduce Pv transmission as measured in a primary
outcome of incidence and secondary outcomes of infection prevalence, seroprevalence, and genetic diversity,
2) Evaluate the safety and tolerability of fMDA, and 3) Measure the cost-effectiveness of fMDA. To maximize
项目总结/摘要
在大多数接近消灭的国家,间日疟原虫(Pv)的比例相对
恶性疟原虫(Pf. falciparum)。大规模给药(MDA)作为一种靶向治疗隐性感染、无症状感染的方法,
推荐用于消除恶性疟原虫,但该建议不适用于间日疟原虫,
证据工具和安全问题我们研究的目的是评估长期影响,安全性,
和成本效益的局灶性MDA(fMDA)的PV传播减少。为了验证我们的假设,
除了标准的积极干预措施,将安全地减少传播,我们提出了一个3年的开放标签,
秘鲁洛雷托地区低流行环境中的CRCT。村庄或集群将被随机分配到对照组或
fMDA。对照组将接受标准干预措施(病媒控制、症状性病例管理和
无症状病例的主动病例检测)。治疗组将接受标准干预加fMDA,
它将利用根治间日疟原虫的新药他非诺喹和新的定量葡萄糖6
磷酸脱氢酶(G6 PD)缺乏快速测试,以支持他非诺喹的安全给药。fMDA
将针对同意和合格的高风险村民,定义为家庭成员和邻居,
最近的Pv指数病例。fMDA将每年进行两轮,在低疟疾期间间隔两个月
赛季,三年多。资格将每年重新评估,并在每一轮fMDA之前。具体
目的是:1)确定fMDA减少PV传播的有效性,如在初级
发病率结果和感染流行率、血清阳性率和遗传多样性的次要结果,
2)评价fMDA的安全性和耐受性; 3)衡量fMDA的成本效果。最大化
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle Sang Hsiang其他文献
Michelle Sang Hsiang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle Sang Hsiang', 18)}}的其他基金
Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru
旨在减少间日疟原虫传播的集中集中药物管理(fMDA),这是秘鲁的一项实用整群随机对照试验
- 批准号:
10488139 - 财政年份:2022
- 资助金额:
$ 126.14万 - 项目类别:
Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
针对坦桑尼亚儿童低密度疟疾感染(LMI)的干预措施的长期健康和社会经济影响
- 批准号:
10609863 - 财政年份:2022
- 资助金额:
$ 126.14万 - 项目类别:
Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
针对坦桑尼亚儿童低密度疟疾感染(LMI)的干预措施的长期健康和社会经济影响
- 批准号:
10328848 - 财政年份:2022
- 资助金额:
$ 126.14万 - 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
- 批准号:
8471646 - 财政年份:2012
- 资助金额:
$ 126.14万 - 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
- 批准号:
9085213 - 财政年份:2012
- 资助金额:
$ 126.14万 - 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
- 批准号:
8662187 - 财政年份:2012
- 资助金额:
$ 126.14万 - 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
- 批准号:
8862355 - 财政年份:2012
- 资助金额:
$ 126.14万 - 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
- 批准号:
8354419 - 财政年份:2012
- 资助金额:
$ 126.14万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 126.14万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 126.14万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 126.14万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 126.14万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 126.14万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 126.14万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 126.14万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 126.14万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 126.14万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 126.14万 - 项目类别: